ATE218880T1 - Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum - Google Patents

Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Info

Publication number
ATE218880T1
ATE218880T1 AT94931793T AT94931793T ATE218880T1 AT E218880 T1 ATE218880 T1 AT E218880T1 AT 94931793 T AT94931793 T AT 94931793T AT 94931793 T AT94931793 T AT 94931793T AT E218880 T1 ATE218880 T1 AT E218880T1
Authority
AT
Austria
Prior art keywords
antibiotic
bacteria
bpi
protein product
administration
Prior art date
Application number
AT94931793T
Other languages
English (en)
Inventor
Jonathan Cohen
Ada H C Kung
Lewis H Lambert Jr
Roger G Ii Little
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE218880T1 publication Critical patent/ATE218880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cash Registers Or Receiving Machines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
AT94931793T 1993-09-22 1994-09-22 Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum ATE218880T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12565193A 1993-09-22 1993-09-22
US27340194A 1994-07-11 1994-07-11
PCT/US1994/011225 WO1995008344A1 (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic

Publications (1)

Publication Number Publication Date
ATE218880T1 true ATE218880T1 (de) 2002-06-15

Family

ID=26823793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931793T ATE218880T1 (de) 1993-09-22 1994-09-22 Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Country Status (12)

Country Link
US (2) US5523288A (de)
EP (1) EP0759774B1 (de)
JP (1) JPH09502987A (de)
AT (1) ATE218880T1 (de)
AU (1) AU695814B2 (de)
CA (1) CA2172245C (de)
DE (1) DE69430823T2 (de)
DK (1) DK0759774T3 (de)
ES (1) ES2178656T3 (de)
NZ (1) NZ275205A (de)
PT (1) PT759774E (de)
WO (1) WO1995008344A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DK0759774T3 (da) * 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
AUPN771596A0 (en) 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
AU735058B2 (en) * 1996-05-10 2001-06-28 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
EA002808B1 (ru) * 1997-05-02 2002-10-31 Интегрэйтед Рисёч Текнолоджи, Ллс Бетаины, используемые в качестве адъювантов для проверки чувствительности и антимикробной терапии
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999052357A1 (en) * 1998-04-14 1999-10-21 Ribogene, Inc. Assays for inhibitors of bacterial translation initiation factor 3
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
US6696239B1 (en) * 2000-04-20 2004-02-24 Biolog, Inc. Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Bpiタンパク質産物またはbpiインヒビターを使用する、周皮細胞増殖の調節
PL362691A1 (en) 2000-12-15 2004-11-02 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US8933029B2 (en) * 2001-08-24 2015-01-13 Carrus Capital Corporation Antimicrobial and anti-inflammatory peptides
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
NZ561169A (en) * 2003-01-21 2008-06-30 Thallion Pharmaceuticals Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
US7300921B2 (en) * 2003-09-11 2007-11-27 Ecopia Biosciences, Inc. Polyene polyketides and methods of production
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
EP1741440A1 (de) * 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
EP2601194B1 (de) 2010-08-03 2016-05-25 Merck Sharp & Dohme Corp. Als antimikrobielle wirkstoffe geeignete fusionierte imidazoylverbindungen
JP6085829B2 (ja) * 2011-01-14 2017-03-01 スペロ トリネム, インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼiv阻害剤
WO2012112438A2 (en) * 2011-02-16 2012-08-23 The Penn State Research Foundation Anti-microbial agents and compositions and methods of production and use thereof
ES2576298T3 (es) 2011-06-20 2016-07-06 Vertex Pharmaceuticals Incorporated Ésteres de fosfato de inhibidores de girasa y topoisomerasa
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US20150150995A1 (en) * 2012-08-09 2015-06-04 Pono Corporation Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof
WO2014160814A1 (en) * 2013-03-26 2014-10-02 Rutgers, The State University Of New Jersey Synthetic and enhanced bacterial killing involving bicyclomycin
KR101811437B1 (ko) * 2015-09-17 2018-01-25 서울대학교산학협력단 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2019018594A1 (en) 2017-07-19 2019-01-24 The University Of North Carolina At Chapel Hill POTENTIATION OF THE ANTIBIOTIC EFFECT

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5028251A (de) * 1973-07-12 1975-03-22
JPS55134471A (en) * 1979-04-04 1980-10-20 Toshiba Corp Sales management system in small-scale computer constitution
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
JPS60128596A (ja) * 1983-12-15 1985-07-09 東芝テック株式会社 電子キヤツシユレジスタ
JPS619790A (ja) * 1984-06-25 1986-01-17 オムロン株式会社 電子式キヤツシユレジスタ
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
ATE123291T1 (de) * 1987-08-11 1995-06-15 Univ New York Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
DE68925275T2 (de) * 1988-06-23 1996-08-22 Ass Cape Cod Inc Endotoxin-bindeprotein und dessen verwendung
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
WO1992009621A1 (en) * 1990-12-03 1992-06-11 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5156665A (en) * 1991-01-03 1992-10-20 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl compounds and isothiazolones and methods of controlling microbes
EP0605653A4 (de) * 1991-09-26 1995-03-15 Incyte Pharma Inc Neue art eines liposaccharid bindendes protein (lbp).
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5439807A (en) * 1992-05-19 1995-08-08 Xoma Corporation Methods for the preparation of endotoxin-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
CA2157927C (en) * 1993-03-12 1999-03-30 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein produc ts
ES2119185T3 (es) * 1993-03-12 1998-10-01 Xoma Corp Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
DK0690872T3 (da) * 1993-03-12 1999-05-10 Xoma Corp Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
DK0759774T3 (da) * 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum

Also Published As

Publication number Publication date
DE69430823D1 (de) 2002-07-18
EP0759774B1 (de) 2002-06-12
AU695814B2 (en) 1998-08-20
DE69430823T2 (de) 2003-02-20
JPH09502987A (ja) 1997-03-25
CA2172245C (en) 2003-04-08
NZ275205A (en) 1998-03-25
US6140306A (en) 2000-10-31
DK0759774T3 (da) 2002-10-07
WO1995008344A1 (en) 1995-03-30
PT759774E (pt) 2002-11-29
EP0759774A1 (de) 1997-03-05
CA2172245A1 (en) 1995-03-30
AU8074094A (en) 1995-04-10
ES2178656T3 (es) 2003-01-01
HK1014155A1 (en) 1999-09-24
US5523288A (en) 1996-06-04

Similar Documents

Publication Publication Date Title
DE69430823D1 (de) Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
DE69527195D1 (de) Anti gram positive bakterielle verfahren und mittel
DE69636228D1 (de) Therapeutische Zusammensetzungen zur Behandlung von Lawsonia intracellularis Infektionen
ATE109624T1 (de) Bakteriocine enthaltende zusammensetzungen zur verwendung als verbesserte breitspektrum- bakterizide und verfahren zur verhütung und behandlung von mikrobiellen infektionen.
ATE421249T1 (de) Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
CA2340304A1 (en) Multicomponent vaccines
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
SE7611103L (sv) Forfarande for framstellning av 2-azetidinonforeningar
EP0772439A4 (de) Neue antibiotika und verfahren zur behandlung von infektionen durch gram-positive bakterien und mykoplasmen
RU94008616A (ru) 2-тиозамещенные карбапенемы, промежуточные соединения для получения, способы получения, фармацевтическая композиция, способ лечения бактериальных инфекций
EP1019084A4 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
Walters et al. Antibiotic-induced Porphyromonas gingivalis LPS release and inhibition of LPS-stimulated cytokines by antimicrobial peptides
ATE182470T1 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
Gadberry et al. Pasteurella pneumotropica isolated from bone and joint infections
WO2005021575A3 (en) Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties
EP0966196A4 (de) Zusammensetzung zur organ-kryokonservierung und behandlung von viralen und bakteriellen infektionen
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
HUP0401586A2 (hu) Baktériumellenes szer
ATE201995T1 (de) Verfahren zur prävention und behandlung der rindermastitis
Achmit et al. Antimicrobial resistance and detection of biofilm in Staphylococcus aureus isolates from Casablanca
FR2696179B1 (fr) Derives de thioalkylthiocarbacephalosporine, procede pour leurs preparations et formulation pharmaceutique les contenant pour le traitement ou la prophylaxie des infections bacteriennes.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee